Moderna Provides Update on Norovirus Vaccine Candidate
5 days ago · Moderna’s mRNA-1403 is a messenger RNA-based trivalent vaccine candidate designed to protect against multiple norovirus genotypes. It is currently being evaluated in the …
A norovirus vaccine could be on the horizon as cases rise
6 days ago · Moderna is testing a norovirus vaccine in a phase three trial, with results available as soon as this year. Norovirus cases are on the rise this winter, with outbreaks already up more …
From Covid to Norovirus: Moderna’s mRNA Tech Takes on
Jan 20, 2025 · Moderna’s vaccine candidate, for instance, tries to create immunity by training the body to target virus-like particles (VLPs) that closely resemble norovirus but which contain no …
Moderna says it’s ‘one step closer’ to a norovirus ... - Yahoo
Jan 13, 2025 · Moderna is recruiting adult participants for Nova 301, its Phase 3 clinical trial evaluating an investigational norovirus vaccine called mRNA-1403. “Stomach bug,” “cruise …
A genetic quirk protects some people from norovirus. Can vaccines ... - BBC
Dec 31, 2024 · Moderna have launched a clinical trial of a messenger RNA (mRNA) norovirus vaccine initially in 18-49 year olds and 60-80 year olds. Meanwhile, Boston-based biotech …
Moderna Announces First Participant Dosed in Pivotal Phase 3 …
Sep 30, 2024 · The vaccine candidate is a trivalent formulation containing mRNA that encodes for virus-like particles (VLPs) designed to protect against multiple norovirus genotypes. About …
A Norovirus Vaccine Is in the Works | TIME
Jan 10, 2025 · Norovirus is surging across the U.S., with case numbers higher now than they've been at the same time in more than a decade, according to the U.S. Centers for Disease …
IDWeek 2024: Moderna’s norovirus vaccine mRNA-1403 shows …
Oct 21, 2024 · At IDWeek 2024, Moderna presented interim results from an ongoing Phase I/II, randomised, observer-blind, placebo-controlled, dose-ranging trial (NCT05992935) for mRNA …
Moderna's mRNA Norovirus Vaccine Trials: To Hurl or Not to …
Dec 9, 2024 · Norovirus vaccines face significant hurdles, with virtually no success from past efforts from HilleVax and Vaxxart. But Moderna's mRNA-1403, now in Phase 3 trials, is based …
Moderna doses first subject in mRNA norovirus vaccine trial
Oct 1, 2024 · US-based pharmaceutical company Moderna has dosed the first subject in the US in its Phase III Nova 301 clinical trial of its investigational norovirus vaccine, mRNA-1403. The …